Novel Analog Platform

About Sequoia Vaccines

Sequoia Vaccines is a private, clinical-stage biotech tackling antimicrobial resistance and oncology with a diversified pipeline. Its lead asset, SEQ-400, is a FimH vaccine for recurrent UTIs, supported by small-molecule programs for ovarian/uterine cancer and cystic fibrosis-related infections. Founded in 2012 (with roots dating to 1999), the company is led by an experienced team, holds a robust patent portfolio, and operates in large, underserved markets with significant unmet medical need. Its strategy aligns with global public health initiatives to reduce antibiotic dependence.

Therapeutic Areas